Patents by Inventor Makoto Ikeya

Makoto Ikeya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220313733
    Abstract: A method for producing renal stromal cells, comprising a step (3) of culturing renal stromal precursors in a medium comprising a platelet derived growth factor receptor agonist to obtain renal stromal cells is provided as a technique for supplying renal stromal cells. This production method can further comprise a step (2) of inducing renal stromal precursors from neural crest cells, and a step (1) of culturing pluripotent stem cells in a medium comprising a GSK3? inhibitor, a TGF? inhibitor, and retinoic acid and/or a derivative thereof to induce neural crest cells.
    Type: Application
    Filed: June 10, 2020
    Publication date: October 6, 2022
    Applicants: Kyoto University, Takeda Pharmaceutical Company Limited
    Inventors: Makoto IKEYA, Daisuke KAMIYA
  • Patent number: 11207303
    Abstract: The present invention relates to a prophylactic or therapeutic agent for fibrodysplasia ossificans progressiva comprising as an active ingredient, at least one compound selected from the group consisting of rapamycin, temsirolimus, everolimus, ridaforolimus, TAFA93, umirolimus, olcorolimus, zotarolimus, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: December 28, 2021
    Assignees: Kyoto University, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Junya Toguchida, Makoto Ikeya, Akira Ohta, Kyosuke Hino
  • Publication number: 20210363485
    Abstract: Provided is a method of producing a somite cell from a pluripotent stem cell, comprising the step of culturing a pluripotent stem cell in a medium comprising a GSK3? inhibitor. Provided is a method of producing a dermatome cell from a somite cell, comprising the step of culturing a somite cell in a medium comprising a GSK3? inhibitor and BMP. Provided is a method of producing a syndetome cell from a sclerotome cell, comprising the steps of culturing a sclerotome cell in a medium comprising FGF and then culturing the cell in a medium comprising BMP and TGF?. Provided is a method of producing a mesenchymal stromal cell from a somite cell, comprising the step of culturing a somite cell in a medium comprising FGF. Provided are methods of producing a myotome cell, a dermatome cell, a sclerotome cell, and a syndetome cell from a pluripotent stem cell through a somite cell by appropriately combining the above methods and known methods.
    Type: Application
    Filed: March 14, 2019
    Publication date: November 25, 2021
    Inventors: Makoto IKEYA, Taiki NAKAJIMA
  • Publication number: 20210198624
    Abstract: A method for producing enteric neural precursors, comprising the steps of: (1) providing enteric neural precursors; and (2) culturing the enteric neural precursors in a medium comprising an ERBB3 agonist and/or an ERBB4 agonist is provided as a technique for allowing enteric neural precursors to proliferate by culture while maintaining their differentiation capacity into enteric nerve cells and glial cells.
    Type: Application
    Filed: August 21, 2019
    Publication date: July 1, 2021
    Inventors: Makoto Ikeya, Yayoi Kamiya, Daisuke Kamiya, Teruyoshi Yamashita, Kazumi Take
  • Patent number: 10947508
    Abstract: Mesenchymal stem cells may be culture for a long period, without using any special apparatus, equipment and the like, in a medium in which seven kinds of nonessential amino acids of glycine, alanine, serine, proline, asparagine, aspartic acid, and glutamic acid are reduced.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: March 16, 2021
    Assignees: AJINOMOTO CO., INC., Kyoto University
    Inventors: Yonghui Jin, Ikue Harata, Sho Senda, Hiroki Ozawa, Tsuyoshi Kobayashi, Junya Toguchida, Makoto Ikeya
  • Publication number: 20210002608
    Abstract: As a technique for proliferating neural crest cells without reducing differentiation capacity, provided is a method for producing neural crest cells, comprising the steps of: (1) obtaining neural crest cells; and (2) suspension-culturing the neural crest cells in a medium comprising a GSK3? inhibitor and a basic fibroblast growth factor (bFGF), wherein the medium comprises the GSK3? inhibitor with a concentration that exhibits an effect equivalent to that exhibited by CHIR99021 with a concentration of higher than 1 ?M and lower than 5 ?M.
    Type: Application
    Filed: November 29, 2018
    Publication date: January 7, 2021
    Inventors: Makoto Ikeya, Yayoi Kamiya
  • Patent number: 10260068
    Abstract: The invention provides a prophylactic agent or therapeutic agent for fibrodysplasia ossificans progressiva, containing as an active ingredient a binding inhibitor that inhibits interaction between activin and activin A receptor type I (ACVR1), or an expression suppressor that suppresses expression of activin.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: April 16, 2019
    Assignees: Sumitomo Dainippon Pharma Co., Ltd., Kyoto University
    Inventors: Kyosuke Hino, Junya Toguchida, Makoto Ikeya
  • Publication number: 20180353485
    Abstract: The present invention relates to a prophylactic or therapeutic agent for fibrodysplasia ossificans progressiva comprising as an active ingredient, at least one compound selected from the group consisting of rapamycin, temsirolimus, everolimus, ridaforolimus, TAFA93, umirolimus, olcorolimus, zotarolimus, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: January 25, 2016
    Publication date: December 13, 2018
    Applicants: Kyoto University, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Junya Toguchida, Makoto Ikeya, Akira Ohta, Kyosuke Hino
  • Patent number: 9921212
    Abstract: A method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia and a therapeutic and/or preventive drug for cartilaginous hyperplasia are provided. The following are provided: a method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising a step of culturing chondroprogenitor cells under conditions in which the cells are brought into contact with a test substance and conditions in which the cells are not brought into contact with the test substance and a step of determining the SOX9 promoter activity, cAMP level, or degree of phosphorylation of CREB in the cells or the extracellular matrix volume in a culture; and a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising as an active ingredient an adenylate cyclase inhibitor.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: March 20, 2018
    Assignee: Kyoto University
    Inventors: Junya Toguchida, Ryuta Nishikomori, Koji Yokoyama, Makoto Ikeya, Toshio Heike
  • Patent number: 9862929
    Abstract: The present invention provides a method of producing a skeletal muscle cell from a pluripotent stem cell, which includes a step of expressing one or more exogenous factors selected from MyoD, Myf5 and nucleic acids encoding them on a pluripotent stem cell.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: January 9, 2018
    Assignee: Kyoto University
    Inventors: Hidetoshi Sakurai, Akihito Tanaka, Knut Woltjen, Makoto Ikeya
  • Publication number: 20170211070
    Abstract: The invention provides a prophylactic agent or therapeutic agent for fibrodysplasia ossificans progressiva, containing as an active ingredient a binding inhibitor that inhibits interaction between activin and activin A receptor type I (ACVR1), or an expression suppressor that suppresses expression of activin.
    Type: Application
    Filed: March 30, 2015
    Publication date: July 27, 2017
    Applicants: Sumitomo Dainippon Pharma Co., Ltd., Kyoto University
    Inventors: Kyosuke Hino, Junya Toguchida, Makoto Ikeya
  • Publication number: 20170198258
    Abstract: Mesenchymal stem cells may be culture for a long period, without using any special apparatus, equipment and the like, in a medium in which seven kinds of nonessential amino acids of glycine, alanine, serine, proline, asparagine, aspartic acid, and glutamic acid are reduced.
    Type: Application
    Filed: February 17, 2017
    Publication date: July 13, 2017
    Applicants: AJINOMOTO CO., INC., Kyoto University
    Inventors: Yonghui JIN, lkue HARATA, Sho SENDA, Hiroki OZAWA, Tsuyoshi KOBAYASHI, Junya TOGUCHIDA, Makoto IKEYA
  • Publication number: 20160177406
    Abstract: A method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia and a therapeutic and/or preventive drug for cartilaginous hyperplasia are provided. The following are provided: a method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising a step of culturing chondroprogenitor cells under conditions in which the cells are brought into contact with a test substance and conditions in which the cells are not brought into contact with the test substance and a step of determining the SOX9 promoter activity, cAMP level, or degree of phosphorylation of CREB in the cells or the extracellular matrix volume in a culture; and a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising as an active ingredient an adenylate cyclase inhibitor.
    Type: Application
    Filed: October 9, 2015
    Publication date: June 23, 2016
    Applicant: KYOTO UNIVERSITY
    Inventors: Junya Toguchida, Ryuta Nishikomori, Koji Yokoyama, Makoto Ikeya, Toshio Heike
  • Publication number: 20140370537
    Abstract: The present invention provides a method of producing a skeletal muscle cell from a pluripotent stem cell, which includes a step of expressing one or more exogenous factors selected from MyoD, Myf5 and nucleic acids encoding them on a pluripotent stem cell.
    Type: Application
    Filed: August 17, 2012
    Publication date: December 18, 2014
    Applicant: KYOTO UNIVERSTIY
    Inventors: Hidetoshi Sakurai, Akihito Tanaka, Knut Woltjen, Makoto Ikeya